Cell therapy for idiopathic pulmonary fibrosis
Part of Lungs & breathing clinical trials.
This trial tests a cell therapy called REGEND007 for people with idiopathic pulmonary fibrosis (IPF). It aims to see if the treatment can help improve walking distance or lung function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 40 and 80 years old.
- You have been diagnosed with idiopathic pulmonary fibrosis (IPF).
- You can walk between 150 and 600 meters in 6 minutes, or your lung function test is above 30% of what's expected.
- You are willing to follow the study procedures and sign a consent form.
- You do not have certain serious health conditions like recent infections, cancer, or unstable heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is testing a new stem cell therapy made from menstrual blood (SC01009) for people with IPF. It may help reduce lung scarring and improve breathing. Participants must already be on standard IPF treatment.
This trial tests a new inhaled treatment made from placental stem cells to see if it's safe and helps slow scarring in the lungs (idiopathic pulmonary fibrosis). The treatment is breathed in through a nebulizer, similar to an asthma inhaler.
This trial tests a new drug called BC006 for people with idiopathic pulmonary fibrosis (IPF), a lung condition that causes scarring. The goal is to see if it can help improve lung function. You may be eligible if you are 40 or older and have a confirmed IPF diagnosis with specific lung test results.
This trial tests a new type of immunotherapy called CAR-DC for people with advanced idiopathic pulmonary fibrosis (IPF) who are not improving on standard treatments and are eligible for a lung transplant but choose not to have one. The goal is to see if this treatment can help slow or stop the disease.
This trial tests a new drug, SB17170, for people with IPF. It aims to see if the drug can help slow down lung damage. You may be eligible if you have a confirmed diagnosis of IPF and meet certain lung function criteria.
This Phase 2 study tests whether an oral medication (INS018_055) can help people with idiopathic pulmonary fibrosis (IPF). You may be a fit if your lung function is in a certain range and your condition is stable.
Hear when a new Idiopathic Pulmonary Fibrosis (IPF) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.